Review concluded regarding general reimbursement for Xarelto®
The Danish Medicines Agency has completed its review of an application for general reimbursement for two new strengths of Xarelto®. The product maintains general reimbursement.
Xarelto® is now also authorised for the prevention of blood clots of the types: apoplexy and systemic embolism in patients with atrial fibrillation as well as for the treatment of deep vein thrombosis and prevention of reccuring deep vein thrombosis and pulmonary embolism.
We find that Xarelto® fulfils the criteria for general reimbursement also in relation to the new indications.
The reimbursement status of Xarelto® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines.
Please find the Reimbursement Committee recommendation and the Danish Medicines Agency’s decision in the factbox to the right (in Danish only).